VALN - Valneva Corp Debt to Book Capitalization Ratio

Valneva SE (VALN) business development relies on epidemic trends and tourist flows, rendering the demand for its drugs cyclical. This market valuation chart for the company demonstrates a current figure of 2.72. Revenues are based on the exclusivity of the Chikungunya fever drug and low price elasticity. However, high R&D costs and complexities regarding the international licensing of new vaccines create significant financial risks.

VALN (Valneva Vaccines) Debt to Book Value history from 07/04/2022 to 10/27/2026

Summary analytical data breakdowns for Valneva Corp (VALN)

- price and consensus price forecast:

Stock Price Valneva SE|VALN - Analyst Consensus Forecast

- market capitalization data:

Market Value Valneva Vaccines|VALN - Value Adjusted for Debt and Cash

- book capitalization data:

Net Assets per Single Share Valneva|VALN - Company Net Assets|Market Capitalization to Book Value Ratio valneva.com|VALN - Company Total Assets

- debt and liquidity data:

Total Debt to Equity Ratio Valneva SE|VALN - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ratio Valneva Pharma|VALN - Company Debts|Debts to Book Capitalization Valneva Vaccines

Fundamental company analysis:Valneva SE

This indicator assesses financial stability by comparing total liabilities to equity to determine the business's degree of reliance on debt financing. By analyzing the ratio of borrowed funds to capitalization, an investor can gauge the margin of safety for Valneva SE (VALN), which is critical when maintaining costly facilities and managing the lengthy development cycle of patent-protected vaccines.

Who Valneva SE competes with